JP7373992B2 - 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法 - Google Patents

過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法 Download PDF

Info

Publication number
JP7373992B2
JP7373992B2 JP2019528861A JP2019528861A JP7373992B2 JP 7373992 B2 JP7373992 B2 JP 7373992B2 JP 2019528861 A JP2019528861 A JP 2019528861A JP 2019528861 A JP2019528861 A JP 2019528861A JP 7373992 B2 JP7373992 B2 JP 7373992B2
Authority
JP
Japan
Prior art keywords
methyl
pyrazole
thiazol
phenyl
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019528861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536785A (ja
JP2019536785A5 (enExample
Inventor
アルシャド、エム．シディキ
ステファン、シブラット
マーティン、デリー
レア、コンスタンティノ－フォルジェ
シャンタル、グラン－メートル
ニコラ、ブリュノー－ラトゥール
ジェラルド、ダブリュ．シップス
アラン、ビー．クーパー
ビバ、オザ
マシュー、タブリュ．コストゥラ
マイケル、ルーサー
ジェッド、レバイン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bantam Pharmaceutical LLC
Original Assignee
Bantam Pharmaceutical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bantam Pharmaceutical LLC filed Critical Bantam Pharmaceutical LLC
Publication of JP2019536785A publication Critical patent/JP2019536785A/ja
Publication of JP2019536785A5 publication Critical patent/JP2019536785A5/ja
Application granted granted Critical
Publication of JP7373992B2 publication Critical patent/JP7373992B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019528861A 2016-11-30 2017-11-29 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法 Active JP7373992B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662428271P 2016-11-30 2016-11-30
US62/428,271 2016-11-30
PCT/US2017/063774 WO2018102453A1 (en) 2016-11-30 2017-11-29 Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases

Publications (3)

Publication Number Publication Date
JP2019536785A JP2019536785A (ja) 2019-12-19
JP2019536785A5 JP2019536785A5 (enExample) 2021-01-14
JP7373992B2 true JP7373992B2 (ja) 2023-11-06

Family

ID=62241871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019528861A Active JP7373992B2 (ja) 2016-11-30 2017-11-29 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法

Country Status (11)

Country Link
US (2) US11325903B2 (enExample)
EP (1) EP3548482A4 (enExample)
JP (1) JP7373992B2 (enExample)
CN (2) CN118930533A (enExample)
AU (1) AU2017366901B2 (enExample)
BR (1) BR112019011044A2 (enExample)
CA (1) CA3081983A1 (enExample)
IL (1) IL266930B2 (enExample)
MX (1) MX2019006299A (enExample)
NZ (1) NZ754827A (enExample)
WO (1) WO2018102453A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3458445B1 (en) 2016-05-18 2021-02-17 Mirati Therapeutics, Inc. Kras g12c inhibitors
AU2017366901B2 (en) * 2016-11-30 2022-09-29 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
BR112019011035A2 (pt) * 2016-11-30 2019-10-15 Bantam Pharmaceutical Llc métodos de uso de compostos pirazol e pirazol substituído e para o tratamento de doenças hiperproliferativas
EP3710439B1 (en) 2017-11-15 2023-02-15 Mirati Therapeutics, Inc. Kras g12c inhibitors
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
EP3790551A4 (en) 2018-05-07 2022-03-09 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2019236966A2 (en) 2018-06-07 2019-12-12 Bantam Pharmaceutical, Llc Methods of treatment of cancer with substituted pyrrole and pyrazole compounds and diagnosis of cancers susceptible to treatment with substituted pyrrole and pyrazole compounds
EP3849536A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
EP3849538A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
ES3004338T3 (en) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Combination therapies
WO2020118066A1 (en) 2018-12-05 2020-06-11 Mirati Therapeutics, Inc. Combination therapies
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
CA3142196A1 (en) 2019-05-31 2020-12-03 Bantam Pharmaceutical, Llc Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative
EP3976605B1 (en) 2019-05-31 2025-08-20 Bantam Pharmaceutical, LLC Methods for making thiazolylpyrazole carboxylic acids and intermediates therefor
JP7622043B2 (ja) 2019-08-29 2025-01-27 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｄ阻害剤
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
IL294048A (en) 2019-12-20 2022-08-01 Mirati Therapeutics Inc sos1 inhibitors
US20230212164A1 (en) * 2020-06-02 2023-07-06 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
KR20230137286A (ko) 2020-09-11 2023-10-04 미라티 테라퓨틱스, 인크. Kras g12c 억제제의 결정 형태
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
US11999753B2 (en) 2020-12-16 2024-06-04 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-KRas inhibitors
KR20240128852A (ko) 2021-12-01 2024-08-27 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 고리형 2-아미노-3-시아노 티오펜 및 유도체
JP2024543976A (ja) * 2021-12-01 2024-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の処置のための環化２－アミノ－３－シアノチオフェン及び誘導体
CN116678810A (zh) * 2022-02-23 2023-09-01 武汉市鼎华双雄生物科技有限责任公司 细胞增殖免疫荧光检测试剂盒及其应用
CN117003651B (zh) * 2023-09-28 2024-01-02 广东嘉博制药有限公司 一种l-肾上腺素的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006522164A (ja) 2003-04-03 2006-09-28 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５のジアリール置換ピラゾール修飾因子
WO2015144290A1 (en) 2014-03-27 2015-10-01 Merck Patent Gmbh Pyridyl piperidines
JP2015534990A (ja) 2012-10-22 2015-12-07 イージェニックス インコーポレイテッド 誤制御されたｅＩＦ４Ｅに関連する疾患又は障害を治療又は予防するための組成物及び方法
JP2020513403A (ja) 2016-11-30 2020-05-14 バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーＢａｎｔａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌ， Ｌｌｃ 置換ピラゾールおよびピロール化合物の使用する方法ならびに過剰増殖性疾患の治療のための方法
JP6707630B2 (ja) 2015-06-01 2020-06-10 バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーＢａｎｔａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌ， Ｌｌｃ 置換ピラゾールおよびピロール化合物、および翻訳開始の阻害およびこれらに関連する疾患および障害の治療のためにこれらを用いる方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1301968B1 (it) 1998-07-30 2000-07-20 Zambon Spa Derivati di eritromicina ad attivita' antibiotica
ES2208227T3 (es) 1999-12-03 2004-06-16 Pfizer Products Inc. Compuestos de heteroarilfenilpirazol como agentes antiinflamatorios/analgesicos.
EP1513534A2 (en) 2002-04-04 2005-03-16 Cv Therapeutics, Inc. Compounds for increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis
JP2006523701A (ja) 2003-04-18 2006-10-19 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャネルブロッカーとしてのビアリール置換チアゾール、オキサゾール、およびイミダゾール
WO2007138110A2 (en) 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
MX2010001462A (es) 2007-08-27 2010-03-01 Basf Se Compuestos de pirazol para controlar plagas de invertebrados.
CN102056907B (zh) 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
CA2722733C (en) 2008-04-28 2016-02-23 Kyorin Pharmaceutical Co., Ltd. Cyclopentylacrylamide derivative
WO2016169886A1 (en) 2015-04-24 2016-10-27 Syngenta Crop Protection Ag Pesticidally active polycyclic derivatives with sulfur substituted five-membered ring heterocyles
AU2017366901B2 (en) * 2016-11-30 2022-09-29 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
CA3142196A1 (en) * 2019-05-31 2020-12-03 Bantam Pharmaceutical, Llc Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006522164A (ja) 2003-04-03 2006-09-28 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５のジアリール置換ピラゾール修飾因子
JP2015534990A (ja) 2012-10-22 2015-12-07 イージェニックス インコーポレイテッド 誤制御されたｅＩＦ４Ｅに関連する疾患又は障害を治療又は予防するための組成物及び方法
WO2015144290A1 (en) 2014-03-27 2015-10-01 Merck Patent Gmbh Pyridyl piperidines
JP6707630B2 (ja) 2015-06-01 2020-06-10 バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーＢａｎｔａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌ， Ｌｌｃ 置換ピラゾールおよびピロール化合物、および翻訳開始の阻害およびこれらに関連する疾患および障害の治療のためにこれらを用いる方法
JP2020513403A (ja) 2016-11-30 2020-05-14 バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーＢａｎｔａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌ， Ｌｌｃ 置換ピラゾールおよびピロール化合物の使用する方法ならびに過剰増殖性疾患の治療のための方法

Also Published As

Publication number Publication date
US20230076820A1 (en) 2023-03-09
NZ754827A (en) 2025-10-31
RU2019120233A3 (enExample) 2021-03-11
EP3548482A1 (en) 2019-10-09
US20190345152A1 (en) 2019-11-14
WO2018102453A1 (en) 2018-06-07
BR112019011044A2 (pt) 2019-10-08
IL266930B2 (en) 2025-09-01
IL266930A (en) 2019-07-31
MX2019006299A (es) 2019-11-12
AU2017366901B2 (en) 2022-09-29
EP3548482A4 (en) 2020-08-19
IL266930B1 (en) 2025-05-01
CN110603254B (zh) 2024-04-12
US11325903B2 (en) 2022-05-10
CN118930533A (zh) 2024-11-12
RU2019120233A (ru) 2021-01-11
CN110603254A (zh) 2019-12-20
CA3081983A1 (en) 2018-06-07
JP2019536785A (ja) 2019-12-19
AU2017366901A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
JP7373992B2 (ja) 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法
US12150934B2 (en) Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases
US9255089B2 (en) Benzimidazolone derivatives as bromodomain inhibitors
KR102438302B1 (ko) 리신 특이적 데메틸라제-1의 억제제
RU2559895C2 (ru) Азотосодержащие производные гетероарилов
CN113544128A (zh) Kras-g12c抑制剂
CA2935071A1 (en) Piperidine-dione derivatives
NZ760657A (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
CN118055933B (zh) 选择性parp1抑制剂及其应用
WO2023224998A1 (en) Inhibitors of parg
KR20250012101A (ko) Parg의 억제제
WO2017073743A1 (ja) 三環性化合物
JP2024534208A (ja) Ｐａｒｐ７阻害剤及びその使用
EP4463452B1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
RU2787994C2 (ru) Замещенные соединения пиразола и способы их применения для лечения гиперпролиферативных заболеваний
HK1220692B (en) Benzimidazolone derivatives as bromodomain inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211019

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230727

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230925

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231024

R150 Certificate of patent or registration of utility model

Ref document number: 7373992

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150